lncRNA ZNF667‑AS1 inhibits ovarian cancer progression by interacting with the TNF signaling pathway

Wu,Fangfang; Zhang,Tianci; Mei,Xiaoyue; Gao,Tianwen

doi:10.3892/etm.2025.12850

lncRNA ZNF667‑AS1 inhibits ovarian cancer progression by interacting with the TNF signaling pathway

Authors:
- Fangfang Wu
- Tianci Zhang
- Xiaoyue Mei
- Tianwen Gao
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, Fuyang Hospital affiliated to Anhui Medical University, Fuyang, Anhui 236000, P.R. China, Anhui Key Laboratory of major autoimmune diseases, School of Pharmacy, Anhui Medical University, Hefei, Anhui 230022, P.R. China, Department of Osteotraumatology of Traditional Chinese Medicine, Anhui University of Traditional Chinese Medicine, Hefei, Anhui 230012, P.R. China, Department of Pharmacy, Fuyang Hospital Affiliated to Anhui Medical University, Fuyang, Anhui 236000, P.R. China
Published online on: March 19, 2025 https://doi.org/10.3892/etm.2025.12850
Article Number: 100
Copyright: © Wu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Ovarian cancer (OC) is the most lethal gynecological malignancy and poses a significant public health burden. The present study explored the function and mechanism of long noncoding RNA (lncRNA) ZNF667‑AS1 in OC progression. The present study conducted a multifaceted evaluation, including transcriptomic analyses, to examine the expression and prognostic value of lncRNA ZNF667‑AS1 in OC via the Cancer Genome Atlas and Genotype‑Tissue Expression data. In vitro experiments on OC cell lines were used to investigate the functional effect of ZNF667‑AS1 via cell proliferation, migration and invasion assays and RNA sequencing and western blotting were used to explore the implicated molecular pathways. ZNF667‑AS1 was significantly underexpressed in OC tissues and cell lines. Its expression levels were positively associated with improved patient prognosis and affected both tumor behavior and tumor microenvironment interactions. Functional analysis confirmed the tumor‑suppressive role of ZNF667‑AS1 and revealed a marked decrease in proliferation, migration and invasion in ZNF667‑AS1‑overexpressing cells. Additionally, ZNF667‑AS1 was identified as a key regulator in the tumor necrosis factor signaling pathway, which suggests a strong link between ZNF667‑AS1 expression and OC progression. The present study identified ZNF667‑AS1 as a potential biomarker for OC prognosis and treatment and illustrated its significant regulatory effects on the TNF pathway and its broader implications in cancer pathobiology.

View Figures

View References

1	Corpus CU and Vulva UOV: Gynecologic Cancer Incidence, United States-2012-2016; Centers for Disease Control and Prevention, US Department of Health and Human Services: Atlanta, GA, USA, 2019.
2	Dellino M, Cascardi E, Laganà AS, Di Vagno G, Malvasi A, Zaccaro R, Maggipinto K, Cazzato G, Scacco S, Tinelli R, et al: Lactobacillus crispatus M247 oral administration: Is it really an effective strategy in the management of papillomavirus-infected women? Infect Agent Cancer. 17(53)2022.PubMed/NCBI View Article : Google Scholar
3	Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 71:209–249. 2021.PubMed/NCBI View Article : Google Scholar
4	Viviani S, Dellino M, Ramadan S, Peracchio C, Marcheselli L, Minoia C and Guarini A: Fertility preservation strategies for patients with lymphoma: A real-world practice survey among Fondazione Italiana Linfomi centers. Tumori. 108:572–577. 2021.PubMed/NCBI View Article : Google Scholar
5	Chen Q, Zhou L, Ma D, Hou J, Lin Y, Wu J and Tao M: LncRNA GAS6-AS1 facilitates tumorigenesis and metastasis of colorectal cancer by regulating TRIM14 through miR-370-3p/miR-1296-5p and FUS. J Transl Med. 20(356)2022.PubMed/NCBI View Article : Google Scholar
6	Yuan JH, Yang F, Wang F, Ma JZ, Guo YJ, Tao QF, Liu F, Pan W, Wang TT, Zhou CC, et al: A Long noncoding RNA activated by TGF-β promotes the invasion-metastasis cascade in hepatocellular carcinoma. Cancer Cell. 25:666–681. 2014.PubMed/NCBI View Article : Google Scholar
7	Tan DSW, Chong FT, Leong HS, Toh SY, Lau DP, Kwang XL, Zhang X, Sundaram GM, Tan GS, Chang MM, et al: Long noncoding RNA EGFR-AS1 mediates epidermal growth factor receptor addiction and modulates treatment response in squamous cell carcinoma. Nat Med. 23:1167–1175. 2017.PubMed/NCBI View Article : Google Scholar
8	Xu Y, Ge Z, Zhang E, Zuo Q, Huang S, Yang N, Wu D, Zhang Y, Chen Y, Xu H, et al: The lncRNA TUG1 modulates proliferation in trophoblast cells via epigenetic suppression of RND3. Cell Death Dis. 8:e3104. 2017.PubMed/NCBI View Article : Google Scholar
9	Lin H, Xu X, Chen K, Fu Z, Wang S, Chen Y, Zhang H, Niu Y, Chen H, Yu H, et al: LncRNA CASC15, MiR-23b cluster and SMAD3 form a novel positive feedback loop to promote epithelial-mesenchymal transition and metastasis in ovarian cancer. Int J Biol Sci. 18:1989–2002. 2022.PubMed/NCBI View Article : Google Scholar
10	Cao HL, Liu ZJ, Huang PL, Yue YL and Xi JN: lncRNA-RMRP promotes proliferation, migration and invasion of bladder cancer via miR-206. Eur Rev Med Pharmacol Sci. 23:1012–1021. 2019.PubMed/NCBI View Article : Google Scholar
11	Kong X, Duan Y, Sang Y, Li Y, Zhang H, Liang Y, Liu Y, Zhang N and Yang Q: LncRNA-CDC6 promotes breast cancer progression and function as ceRNA to target CDC6 by sponging microRNA-215. J Cell Physiol. 234:9105–9117. 2018.PubMed/NCBI View Article : Google Scholar
12	Xiao Z, Liu Y, Zhao J, Li L, Hu L, Lu Q, Zeng Z, Liu X, Huang D, Yang W and Xu Q: Long noncoding RNA LINC01123 promotes the proliferation and invasion of hepatocellular carcinoma cells by modulating the miR-34a-5p/TUFT1 axis. Int J Biol Sci. 16:2296–2305. 2020.PubMed/NCBI View Article : Google Scholar
13	Vrba L, Garbe JC, Stampfer MR and Futscher BW: A lincRNA connected to cell mortality and epigenetically-silenced in most common human cancers. Epigenetics. 10:1074–1083. 2015.PubMed/NCBI View Article : Google Scholar
14	Chen X, Huang Y, Shi D, Nie C, Luo Y, Guo L, Zou Y and Xie C: LncRNA ZNF667-AS1 Promotes ABLIM1 Expression by Adsorbing microRNA-1290 to Suppress Nasopharyngeal Carcinoma Cell Progression. Onco Targets Ther. 13:4397–4409. 2020.PubMed/NCBI View Article : Google Scholar
15	Yang H, Cai MY, Rong H, Ma LR and Xu YL: ZNF667-AS1, a positively regulating MEGF10, inhibits the progression of uveal melanoma by modulating cellular aggressiveness. J Biochem Mol Toxicol. 35(e22732)2021.PubMed/NCBI View Article : Google Scholar
16	Wang D, Wang Y, Zou X, Shi Y, Liu Q, Huyan T, Su J, Wang Q, Zhang F, Li X and Tie L: FOXO1 inhibition prevents renal ischemia-reperfusion injury via cAMP-response element binding protein/PPAR-γ coactivator-1α-mediated mitochondrial biogenesis. Br J Pharmacol. 177:432–448. 2020.PubMed/NCBI View Article : Google Scholar
17	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
18	Feng Y, Zhang Z, Yang H, Miao F, Li Y, Zhang M, Cao Y and Li M: The lncRNA TPTEP1 suppresses PI3K/AKT signalling and inhibits ovarian cancer progression by interacting with PTBP1. J Cell Mol Med. 28(e70106)2024.PubMed/NCBI View Article : Google Scholar
19	Huang Z, Senocak F, Jayaraman A and Hahn J: Integrated modeling and experimental approach for determining transcription factor profiles from fluorescent reporter data. BMC Syst Biol. 2(64)2008.PubMed/NCBI View Article : Google Scholar
20	Cervena K, Vodenkova S and Vymetalkova V: MALAT1 in colorectal cancer: Its implication as a diagnostic, prognostic and predictive biomarker. Gene. 843(146791)2022.PubMed/NCBI View Article : Google Scholar
21	Qiu MT, Hu JW, Yin R and Xu L: Long noncoding RNA: An emerging paradigm of cancer research. Tumour Biol. 34:613–620. 2013.PubMed/NCBI View Article : Google Scholar
22	He Y, Meng XM, Huang C, Wu BM, Zhang L, Lv XW and Li J: Long noncoding RNAs: Novel insights into hepatocelluar carcinoma. Cancer Lett. 344:20–27. 2014.PubMed/NCBI View Article : Google Scholar
23	Katsushima K, Natsume A, Ohka F, Shinjo K, Hatanaka A, Ichimura N, Sato S, Takahashi S, Kimura H, Totoki Y, et al: Targeting the Notch-regulated non-coding RNA TUG1 for glioma treatment. Nat Commun. 7(13616)2016.PubMed/NCBI View Article : Google Scholar
24	Huang Y, Zhang J, Hou L, Wang G, Liu H, Zhang R, Chen X and Zhu J: LncRNA AK023391 promotes tumorigenesis and invasion of gastric cancer through activation of the PI3K/Akt signaling pathway. J Exp Clin Cancer Res. 36(194)2017.PubMed/NCBI View Article : Google Scholar
25	Zhao LP, Li RH, Han DM, Zhang XQ, Nian GX, Wu MX, Feng Y, Zhang L and Sun ZG: Independent prognostic Factor of low-expressed LncRNA ZNF667-AS1 for cervical cancer and inhibitory function on the proliferation of cervical cancer. Eur Rev Med Pharmacol Sci. 21:5353–5360. 2017.PubMed/NCBI View Article : Google Scholar
26	Vrba L and Futscher BW: Epigenetic silencing of MORT is an early event in cancer and is associated with luminal, receptor positive breast tumor subtypes. J Br Cancer. 20(198)2017.PubMed/NCBI View Article : Google Scholar
27	Vrba L and Futscher BW: Epigenetic silencing of lncRNA MORT in 16 TCGA cancer types. F1000Research. 7(211)2018.PubMed/NCBI View Article : Google Scholar
28	Liu M, Yi Y and Zhao M: Effect of dexmedetomidine anesthesia on perioperative levels of TNF-α and IL-6 in patients with ovarian cancer. Oncol Lett. 17:5517–5522. 2019.PubMed/NCBI View Article : Google Scholar
29	Gupta M, Babic A, Beck AH and Terry K: TNF-α expression, risk factors and inflammatory exposures in ovarian cancer: Evidence for an inflammatory pathway of ovarian carcinogenesis? Hum Pathol. 54:82–91. 2016.PubMed/NCBI View Article : Google Scholar
30	Felices M, Chu S, Kodal B, Bendzick L, Ryan C, Lenvik AJ, Boylan KLM, Wong HC, Skubitz APN, Miller JS and Geller MA: IL-15 super-agonist (ALT-803) enhances natural killer (NK) cell function against ovarian cancer. Gynecol Oncol. 145:453–456. 2017.PubMed/NCBI View Article : Google Scholar